ID   KALS-1
AC   CVCL_1323
SY   KALS1
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03470951
DR   BioSample; SAMN10987840
DR   CCLE; KALS1_CENTRAL_NERVOUS_SYSTEM
DR   Cell_Model_Passport; SIDM00613
DR   CGH-DB; 142-1
DR   ChEMBL-Cells; CHEMBL3308235
DR   ChEMBL-Targets; CHEMBL2366155
DR   Cosmic; 687572
DR   Cosmic; 907271
DR   Cosmic; 2367530
DR   Cosmic; 2516020
DR   Cosmic-CLP; 907271
DR   DepMap; ACH-000231
DR   GDSC; 907271
DR   GEO; GSM887194
DR   GEO; GSM888267
DR   GEO; GSM1669972
DR   IARC_TP53; 21426
DR   JCRB; IFO50434
DR   LiGeA; CCLE_316
DR   LINCS_LDP; LCL-1380
DR   PharmacoDB; KALS1_726_2019
DR   Wikidata; Q54899463
RX   CelloPub=CLPUB00062;
RX   PubMed=16232199;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: 90 hours (PubMed=25984343); ~38 hours (lot 09142016) (JCRB).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for PTEN p.Arg130Ter (c.388C>T) (CCLE; Cosmic-CLP).
CC   Sequence variation: TERT c.228C>T (-124C>T); in promoter (PubMed=31068700).
CC   Sequence variation: Homozygous for TP53 p.Ser241Phe (c.722C>T) (CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.68%; Native American=0%; East Asian, North=78.93%; East Asian, South=16.7%; South Asian=1.01%; European, North=0%; European, South=1.68% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 9
ST   D13S317: 10
ST   D16S539: 11,13
ST   D18S51: 14,19
ST   D19S433: 13,15.2
ST   D21S11: 29,32
ST   D2S1338: 18,22
ST   D3S1358: 16,18
ST   D5S818: 9
ST   D7S820: 10,12
ST   D8S1179: 12,13
ST   FGA: 21,23
ST   Penta D: 9,10
ST   Penta E: 12,15
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C3058; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   74Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 23
//
RX   CelloPub=CLPUB00062;
RA   Lee S., Iryo O., Sugita Y., Moriyama T., Tokunaga T., Maruiwa H.,
RA   Shigemori M., Kuramoto S., Yokoyama S.;
RT   "Characterization of an established human malignant glioma cell line,
RT   KALS-1.";
RL   Hum. Cell 3:259-260(1990).
//
RX   PubMed=16232199; DOI=10.1111/j.1349-7006.2005.00099.x;
RA   Saigusa K., Hashimoto N., Tsuda H., Yokoi S., Maruno M., Yoshimine T.,
RA   Aoyagi M., Ohno K., Imoto I., Inazawa J.;
RT   "Overexpressed Skp2 within 5p amplification detected by array-based
RT   comparative genomic hybridization is associated with poor prognosis of
RT   glioblastomas.";
RL   Cancer Sci. 96:676-683(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//